SCHEMBL18095798

SCHEMBL18095798

O=C(O)COc1c(Cl)cccc1C=C1SC(=S)NC1=O

nearest known ligand 0.60

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 3/20 0.60
▸ PDE4B Q07343 1/20 0.54
▸ GSK3B P49841 1/20 0.53
▸ NAT1 P18440 5/20 0.51
▸ KMT2A Q03164 1/20 0.50
▸ PTP4A3 O75365 5/20 0.49
▸ CRHBP P24387 2/20 0.49
▸ CRHR2 Q13324 2/20 0.49
▸ PLA2G1B P04054 1/20 0.47
▸ ATG4B Q9Y4P1 1/20 0.47
▸ CA2 P00918 1/20 0.46
▸ EPHX1 P07099 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18095797 1.00 PIM1 (0.60) PIM1PDE4BGSK3BNAT1KMT2A
SCHEMBL18102961 1.00 PIM1 (0.60) PIM1PDE4BGSK3BNAT1KMT2A
SCHEMBL18102903 0.85 PDE4B (0.73) PDE4BGSK3BNAT1KMT2APTP4A3
SCHEMBL18102863 0.82 PIM1 (0.51) PIM1PDE4BGSK3BNAT1KMT2A
SCHEMBL18102905 0.81 GSK3B (0.75) PIM1PDE4BGSK3BNAT1KMT2A
SCHEMBL12892144 0.81 GSK3B (0.75) PIM1PDE4BGSK3BNAT1KMT2A
SCHEMBL18102850 0.79 MGAM (0.63) PIM1PDE4BGSK3BNAT1PTP4A3
SCHEMBL18102859 0.78 PTP4A3 (0.58) PIM1GSK3BNAT1PTP4A3CRHBP
SCHEMBL18103052 0.77 PIM1 (0.74) PIM1PDE4BGSK3BNAT1PTP4A3
SCHEMBL18102944 0.77 PIM1 (0.74) PIM1PDE4BGSK3BNAT1PTP4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10501413-B2 Inhibitors of the Notch transcriptional activation complex and methods for use of the same UNIVERSITY OF MIAMI (US) 2019-12-10 — — US disclosed
US-20180086700-A1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-29 — — US disclosed
EP-3282846-A1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME University of Miami (US) 2018-02-21 — — EP disclosed
WO-2016154255-A1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME UNIVERSITY OF MIAMI (US) 2016-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10501413-B2 Inhibitors of the Notch transcriptional activation complex and methods for use of the same NOTCH1, CBFB, HES1 PIM1 2196/4885PDE4B 3826/4885GSK3B 1070/4885
US-20180086700-A1 INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME NOTCH1, CBFB, HES1 PIM1 2196/4885PDE4B 3826/4885GSK3B 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback